| Schedule of Segment Information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Three Months Ended September 30, 2024 |
|
Sales1 |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
14,629 |
|
$ |
— |
|
$ |
14,629 |
Cost of goods - product revenue |
|
|
(5,285) |
|
|
— |
|
|
(5,285) |
Research and development |
|
|
(842) |
|
|
(8,604) |
|
|
(9,446) |
Selling, general and administrative |
|
|
(11,396) |
|
|
(10,597) |
|
|
(21,993) |
Asset impairment |
|
|
— |
|
|
— |
|
|
— |
Other income (expense) |
|
|
504 |
|
|
(5,034) |
|
|
(4,530) |
Income tax expense |
|
|
— |
|
|
(69) |
|
|
(69) |
Segment loss |
|
$ |
(2,390) |
|
|
(24,304) |
|
$ |
(26,694) |
Note 1: As reported by Journey, inclusive of expense eliminated in consolidation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Nine Months Ended September 30, 2024 |
|
Sales1 |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
42,514 |
|
$ |
41 |
|
$ |
42,555 |
Cost of goods - product revenue |
|
|
(18,642) |
|
|
0 |
|
|
(18,642) |
Research and development |
|
|
(9,639) |
|
|
(37,302) |
|
|
(46,941) |
Selling, general and administrative |
|
|
(30,144) |
|
|
(30,723) |
|
|
(60,867) |
Asset impairment |
|
|
— |
|
|
(2,649) |
|
|
(2,649) |
Other expense |
|
|
(282) |
|
|
(7,738) |
|
|
(8,020) |
Income tax refund |
|
|
— |
|
|
24 |
|
|
24 |
Segment loss |
|
$ |
(16,193) |
|
$ |
(78,347) |
|
$ |
(94,540) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Three Months Ended September 30, 2023 |
|
Sales1 |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
34,539 |
|
$ |
213 |
|
$ |
34,752 |
Cost of goods - product revenue |
|
|
(6,429) |
|
|
— |
|
|
(6,429) |
Research and development |
|
|
(2,229) |
|
|
(18,119) |
|
|
(20,348) |
Selling, general and administrative |
|
|
(8,636) |
|
|
(13,097) |
|
|
(21,733) |
Other income (expense) |
|
|
(361) |
|
|
3,536 |
|
|
3,175 |
Income Tax expense |
|
|
(95) |
|
|
(46) |
|
|
(141) |
Segment income (loss) |
|
$ |
16,789 |
|
$ |
(27,513) |
|
$ |
(10,724) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Nine Months Ended September 30, 2023 |
|
Sales1 |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
63,924 |
|
$ |
643 |
|
$ |
64,567 |
Cost of goods - product revenue |
|
|
(20,645) |
|
|
— |
|
|
(20,645) |
Research and development |
|
|
(6,036) |
|
|
(85,959) |
|
|
(91,995) |
Selling, general and administrative |
|
|
(34,069) |
|
|
(37,443) |
|
|
(71,512) |
Asset impairment |
|
|
(3,143) |
|
|
— |
|
|
(3,143) |
Other Income |
|
|
(1,646) |
|
|
(654) |
|
|
(2,300) |
Income Tax Expense |
|
|
(95) |
|
|
(47) |
|
|
(142) |
Segment loss |
|
$ |
(1,710) |
|
$ |
(123,460) |
|
$ |
(125,170) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
September 30, 2024 |
|
Sales |
|
Development |
|
Total Assets |
Intangible assets, net |
|
$ |
17,844 |
|
$ |
— |
|
$ |
17,844 |
Tangible assets |
|
|
46,200 |
|
|
63,041 |
|
|
109,241 |
Total segment assets |
|
$ |
64,044 |
|
$ |
63,041 |
|
$ |
127,085 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
December 31, 2023 |
|
Sales |
|
Development |
|
Total Assets |
Intangible assets, net |
|
$ |
20,287 |
|
$ |
— |
|
$ |
20,287 |
Tangible assets |
|
|
56,561 |
|
|
90,678 |
|
|
147,239 |
Total segment assets |
|
$ |
76,848 |
|
$ |
90,678 |
|
$ |
167,526 |
|